What "early onset" means
Alzheimer's that starts before about 65 is called early-onset. MedlinePlus puts its signs between the thirties and the mid-sixties and says it accounts for less than 10 percent of cases. Late-onset disease starts in the mid-sixties or later and is the common form.
Where APOE4 fits
APOE4 is an extensively studied genetic risk factor for late-onset Alzheimer's. One copy raises risk, and two copies raise it further (MedlinePlus). The 2011 lifetime-risk analysis also found that APOE4 raises the risk of early-onset as well as late-onset disease (Genin, 2011).
Raising risk is not the same as guaranteeing. Not everyone with Alzheimer's has APOE4, and not everyone with APOE4 develops it (MedlinePlus).
What causes the inherited early-onset forms
Some early-onset cases run in families and result from changes in one of three genes: APP, PSEN1 or PSEN2. These follow an autosomal dominant pattern, so one altered copy is enough (MedlinePlus). They are different genes from APOE, so an APOE result does not tell you about them.
MedlinePlus says only some early-onset cases are explained by these genes, so a family history of early onset and a known gene are not the same thing.
Does having two copies change the picture?
Two numbers are often mixed up here, and they answer different questions.
- When symptoms start, on average. A study of 10,039 people in clinical cohorts, and 3,297 with brain pathology data, found symptoms began at an average age of around 65 in people with two copies, earlier than in people with two copies of APOE3. The authors also report near-complete Alzheimer's biology in these people and describe two copies as a genetic form of Alzheimer's disease (Fortea, 2024). That is a statement about disease biology and the average start of symptoms in these research cohorts. It does not say every person with two copies has dementia before 65.
- How many people have Alzheimer's by a given age. The lifetime-risk analysis estimated that for two copies, about 2 to 4 in 100 have Alzheimer's by 65 and 51 to 60 in 100 by 85 (Genin, 2011, Table 3A). Those estimates combine seven case-control studies from Europe and the US, with participants of European ancestry, and incidence data from Rochester, Minnesota. They describe those populations, not a timetable for any one person.
The first is an average age of first symptoms among people who developed them. The second counts everyone with the genotype, including people who stay well. Both can be true: the average start of symptoms can be near 65 while most people with two copies do not yet have Alzheimer's at 65. The full table is on risk by age.
What to do with this
- Early-onset Alzheimer's in your family is a reason to talk with a doctor or genetic counselor about whether genetic testing could help. Joint ACMG and National Society of Genetic Counselors guidelines set out genetic counseling for Alzheimer's and a framework for who may benefit from testing (Goldman, 2011).
- If you carry APOE4, the next step is yours to choose, not a verdict. Start with your APOE4 result: one clear next step, then the first 7 days guide.
- Apply to join Phoenix: 750+ APOE4 carriers, 27 APOE4 biomarkers tracked, 60-day money-back guarantee. Phoenix earns only from memberships, never from anything it recommends.